A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
25 March 2026
Read original ↗
🅇 This trial is currently recruiting participants in the UK
Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.
🔬 This trial is currently recruiting participants
If you match the criteria below, you may be able to take part. Ask your doctor about this trial or contact the trial team directly.
Status
Recruiting
Trial Phase
PHASE3
Who Can Join
ALL
Age Range
1 Year – 25 Years
About This Trial
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment.
The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab compared with placebo, both administered by intravenous (IV) infusion, in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) aged 1 to 25 years, on standard insulin therapy.
Run by
Sanofi
⚕️ Before you apply: Talk to your GP or specialist about whether this trial might be right for you. Never stop existing treatment without medical advice. Trial ID: NCT07088068